Kirszberg Clarice, Rumjanek Vivian M, Monteiro Robson Q
Departamento de Bioquímica Médica, Instituto de Ciências Biomédicas, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Cidade Universitária, Ilha do Fundão, Avenida Bauhínia 400, Rio de Janeiro, CEP-21941-590, Rio de Janeiro, Brazil.
Thromb Res. 2005;115(1-2):123-9. doi: 10.1016/j.thromres.2004.08.001.
A number of studies indicate that coagulation proteases play significant roles in cancer biology. Melanoma is a highly metastatic cancer, and there is evidence that thrombin contributes to this aggressive pattern. However, few studies correlate this type of cancer with formation of the prothrombinase complex, which is responsible for conversion of prothrombin into thrombin in the coagulation system. The aim of this study was to investigate the assembly and regulation of prothrombinase complex on the murine melanoma cell line, B16F10. B16F10 cells were unable to activate prothrombin except when previously incubated with factor Xa. This effect was dependent on factor Xa binding to cell membranes, since no activation was detected with Gla-domainless factor Xa. The thrombin formation by B16F10-bound factor Xa was enhanced approximately 10 fold in the presence of factor Va, indicating the assembly of prothrombinase complex. Differently from platelets, B16F10-assembled prothrombinase complex was inhibited by prothrombin fragment 1 but not by fragment 2. In addition, bothrojaracin, a specific ligand of proexosite I on prothrombin, caused a significant decrease in the zymogen activation. Our data demonstrate that B16F10 melanoma cells generate thrombin by promoting assembly of the prothrombinase complex. This ability might be correlated with the increased metastatic potential of this cell line. Moreover, B16F10-assembled prothrombinase complex seems to be modulated in a different way from that found for the physiological complex assembled on platelets.
多项研究表明,凝血蛋白酶在癌症生物学中发挥着重要作用。黑色素瘤是一种高度转移性癌症,有证据表明凝血酶促成了这种侵袭性模式。然而,很少有研究将这类癌症与凝血酶原酶复合物的形成联系起来,凝血酶原酶复合物在凝血系统中负责将凝血酶原转化为凝血酶。本研究旨在调查小鼠黑色素瘤细胞系B16F10上凝血酶原酶复合物的组装和调节情况。B16F10细胞无法激活凝血酶原,除非之前与因子Xa孵育。这种效应依赖于因子Xa与细胞膜的结合,因为无Gla结构域的因子Xa未检测到激活作用。在因子Va存在的情况下,B16F10结合的因子Xa形成的凝血酶增加了约10倍,表明凝血酶原酶复合物的组装。与血小板不同,B16F10组装的凝血酶原酶复合物被凝血酶原片段1抑制,但不被片段2抑制。此外,凝血酶原上外切位点I的特异性配体Bothrojaracin导致酶原激活显著降低。我们的数据表明,B16F10黑色素瘤细胞通过促进凝血酶原酶复合物的组装来产生凝血酶。这种能力可能与该细胞系转移潜能的增加有关。此外,B16F10组装的凝血酶原酶复合物似乎以与血小板上组装的生理复合物不同的方式受到调节。